Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders

Abstract

Substantial advance supports that CMTM2 serve as an important performer in physiological and pathological processes. However, very little is clear about the relationship between CMTM2 and HBV-related disorders. Here, for the first time, we explore that whether or not serum CMTM2 is involved in HBV-related diseases. We found that CMTM2 values were significantly lower in patients compared to healthy control (p <0.001), using ELISA assay. Furthermore, serum CMTM2 levels were negatively correlated with HBV DNA levels in CHB patients but not correlated with the serum levels of ALT and AST. Serum CMTM2 concentrations were not correlated with the serum levels of ALT, AST and HBV DNA load in HBLC and HCC patients. In addition, analysis of the ROC curve indicated that CMTM2 levels were significantly associated with the diagnostic value of HBV-related disorders. Finally, downregulation of CMTM2 was observed in HBV-infected cell model. CMTM2 degradation could be attributed to HBx-activated Lys48 (K48)-linked polyubiquitination, which was abolished by treatment with the proteasome inhibitor MG132. HBV infection suppresses CMTM2 expression by activating ubiquitin-proteasome system. Serum CMTM2 levels can be adopted as an effective indicator of the pathogenesis of HBV-related disorders.

Development of a novel immune infiltration-related diagnostic model for Alzheimer’s disease using bioinformatic strategies

“…CMTM2 is a member of a newly found gene family (chemokine-like factor-like MARVEL transmembrane domain-containing family members), the members which have been reported to be involved in various tumors, reproduction, and immunity ( 29 ). CMTM2 has been reported in spermiogenesis ( 30 ), hepatocellular carcinoma, HBV-related disorders ( 31 ), and gastric cancer ( 32 ). However, its role in immunity and the nervous system is unknown.…”

Key common genes and pathways in ulcerative colitis and ankylosing spondylitis based on bioinformatics analysis

“…According to a study in Chinese cohort, individuals with HBV-related liver disorder exhibited notably lower expression levels of CMTM2 in their serum compared to healthy subjects. In addition, it has been demonstrated that serum CMTM2 correlates with the DNA load of HBV and may be utilized to distinguish between HBV patients and healthy individuals [38]. Comprehensive histologic and microarray analysis of OA patients revealed reduced CMTM2 expression in OA patients compared to healthy controls [39].…”

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma

“…Consequently, serum CMTM2 levels may serve as a reliable predictor of the pathogenesis of HBV-related illness. 30 Guo et al found that the expression of CMTM2 in HCC tissues was notably lower than that in para-cancerous tissues. 33 They also noticed that it was profoundly associated with tumor grade in HCC patients.…”

“…14 In recent years, a large number of studies have proven that CMTM2 is a mutated gene with an inhibitory effect on tumor cell migration and invasion, especially in stomach cancer. [30][31][32] More importantly, CMTM2 can be used as a prognostic biological indicator of stomach cancer, playing a key role in the progression of the disease, particularly in diffuse gastric cancer. [30][31][32] By utilizing ELISA, some researchers realized that CMTM2 values were considerably lower in chronic hepatitis B patients than in healthy controls.…”